Parathyroid Hormone-Related Protein Analogs as Osteoporosis Therapies

Pedro Esbrit, Sabina Herrera, Sergio Portal-Núñez, Xavier Nogués, Adolfo Díez-Pérez

Research output: Contribution to journalReview articleResearchpeer-review

22 Citations (Scopus)


© 2015, Springer Science+Business Media New York. The only bone anabolic agent currently available for osteoporosis treatment is parathyroid hormone (PTH)—either its N-terminal 1–34 fragment or the whole molecule of 1–84 aminoacids—whose intermittent administration stimulates new bone formation by targeting osteoblastogenesis and osteoblast survival. PTH-related protein (PTHrP) is an abundant factor in bone which shows N-terminal homology with PTH and thus exhibits high affinity for the same PTH type 1 receptor in osteoblasts. Therefore, it is not surprising that intermittently administered N-terminal PTHrP peptides induce bone anabolism in animals and humans. Furthermore, the C-terminal region of PTHrP also elicits osteogenic features in vitro in osteoblastic cells and in various animal models of osteoporosis. In this review, we discuss the current concepts about the cellular and molecular mechanisms whereby PTHrP may induce anabolic actions in bone. Pre-clinical studies and clinical data using N-terminal PTHrP analogs are also summarized, pointing to PTHrP as a promising alternative to current bone anabolic therapies.
Original languageEnglish
Pages (from-to)359-369
JournalCalcified Tissue International
Issue number4
Publication statusPublished - 1 Apr 2016


  • Bone anabolic therapy
  • Bone formation
  • PTHrP


Dive into the research topics of 'Parathyroid Hormone-Related Protein Analogs as Osteoporosis Therapies'. Together they form a unique fingerprint.

Cite this